Literature DB >> 28921677

Clinical profile of hepatitis C virus infection in a developing country: India.

Ramit Mahajan1, Vandana Midha2, Omesh Goyal1, Varun Mehta1, Vikram Narang3, Kirandeep Kaur4, Arshdeep Singh1, Dharmatma Singh1, Rishu Bhanot2, Ajit Sood1.   

Abstract

BACKGROUND AND AIM: The epidemiology and clinical profile of hepatitis C virus (HCV) varies worldwide, and data from developing countries are sparse. The aim of the present study was to assess the clinical profile of HCV infection in a developing country in South-East Asia (India).
METHODS: This observational study assessed patient demographics, viral characteristics, risk factors for virus acquisition, and disease characteristics in HCV patients diagnosed between January 2004 and December 2015.
RESULTS: Of 8035 patients who were diagnosed with HCV infection, a majority were men (68.3%), middle aged (52.2%), and from low (34%) to middle (46%) socioeconomic status and rural population (69.8%). Eighty-two percent had identifiable risk factors, the most common being history of dental treatment (52%) and therapeutic injections with reusable syringes/needles (45%). Household contacts of index patients had high prevalence of HCV (15.3%). Common genotypes were genotype 3 (70.4%) and genotype 1 (19.3%). Although a majority of patients were either asymptomatic (54.8%) or had non-specific symptoms (6.7%) at presentation, a significant proportion (9.3%) had advanced liver disease. Presentation with cirrhosis (38.8%) was associated with male gender, higher age at time of virus detection, rural residence, alcohol or opium intake, and coinfections with hepatitis B virus or human immunodeficiency virus.
CONCLUSIONS: Hepatitis C virus infection in northern India is seen more commonly in men, the middle aged and people from rural background and low to middle socioeconomic status. The common possible risk factors are dental treatment and exposure to reused syringes and needles. Although the most common presentation is incidental detection, a large number of patients present with advanced liver disease.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  clinical; clinical profile; epidemiology; hepatitis C; viral hepatitis

Mesh:

Year:  2018        PMID: 28921677     DOI: 10.1111/jgh.13995

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.

Authors:  Phimpha Paboriboune; Thomas Vial; Philavanh Sitbounlang; Stéphane Bertani; Christian Trépo; Paul Dény; Francois-Xavier Babin; Nicolas Steenkeste; Pascal Pineau; Eric Deharo
Journal:  Virol Sin       Date:  2018-06-13       Impact factor: 4.327

2.  Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis.

Authors:  Bertha Huarez; Akram Hernández-Vásquez; Diego Azañedo; Rodrigo Vargas-Fernández; Daniel Comandé; Ysela Agüero-Palacios
Journal:  Arch Virol       Date:  2022-10-05       Impact factor: 2.685

3.  Nutritional Status among Patients with Chronic Hepatitis C in the North-Eastern Part of India: A Cross-Sectional Study from the Tribal Belt of India.

Authors:  Santosh Kumar Singh; Bhushan Dattatray Kamble; Gireesh Kumar Dhaked; Parashuram Naik Korra; Muthathal Subramanian
Journal:  Maedica (Bucur)       Date:  2022-06

4.  Epidemiological correlates of hepatitis C infection- A case control analysis from a tertiary care hospital.

Authors:  Pranjl Sharma; Mahesh Satija; Anurag Chaudhary; Surinderpal Singh; Sarit Sharma; Sangeeta Girdhar; Vikram Kumar Gupta; Priya Bansal
Journal:  J Family Med Prim Care       Date:  2022-05-14

5.  The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.

Authors:  Ajit Sood; A Suryaprasad; A Trickey; S Kanchi; V Midha; M A Foster; E Bennett; S Kamili; F Alvarez-Bognar; S Shadaker; V Surlikar; R Garg; P Mittal; S Sharma; M T May; P Vickerman; F Averhoff
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.